Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Portola

Sort by

Portola: Approval of AndexXa is a Major Positive (PTLA, Buy, $41.19)

Friday, May 4, 2018 · 12:18 pm

Read More

Portola: Why I Think that AndexXa is Likely to be Approved (PTLA, Buy, $36.44)

Thursday, March 15, 2018 · 9:57 am

Read More

Portola: Uncertainty on AndexXa Approval Leads to 30% Decline in Stock Price (PTLA, Buy, $31.16)

Thursday, March 1, 2018 · 11:54 am

Read More

Portola Announces a Delay in PDUFA Date for AndexXa (PTLA, Buy, $54.86)

Monday, December 25, 2017 · 10:28 am

Read More

Portola: US Launch of Bevyexxa Is Scheduled for Early January 2018 (PTLA, Buy, $50.03)

Tuesday, December 19, 2017 · 1:07 pm

Read More

Portola: Management Guides to a Highly Probable US Launch of Bevyexxa in the December to February Timeframe (PTLA, Buy, $50.52)

Tuesday, November 7, 2017 · 11:43 am

Read More

Portola: Reiterating Buy and Refuting Recent Negative Blog by Adam F-stein (PTLA, Buy, $54.12)

Sunday, September 24, 2017 · 9:30 am

Read More

Portola: September 4 Conference Call Provides Update on Potential Launch Date for Bevyxxa and Announces Price (PTLA, Buy, $57.29)

Wednesday, September 6, 2017 · 10:18 am

Read More

Portola Pharmaceuticals: AndexXa BLA Resubmitted; Reiterating Buy (PTLA, $61.41, Buy)

Tuesday, August 8, 2017 · 12:45 pm

Read More

Portola Pharmaceuticals:  Betrixaban Approval Triggers Big Stock Move-Now What Do We Do? (PTLA, Buy, $55.42)

Thursday, June 29, 2017 · 9:09 am

Read More

Portola: Reiterating Buy Prior to June 24th PDUFA Date for Betrixaban (PTLA, Buy, $39.35)

Thursday, June 22, 2017 · 11:08 am

Read More

Portola Pharmaceuticals: Initiating Coverage with a Buy (PTLA, $40.05)

Thursday, May 4, 2017 · 10:47 am

Read More

There are 12 reports on file.

« Back to Company Reports Index